Pentose Phosphate Pathway and NADPH Homeostasis
Two Branches With Different Logic
| Branch | Reactions | Products | Regulation |
|---|---|---|---|
| Oxidative | G6PD, 6-phosphogluconolactonase, 6PGD | NADPH, ribulose-5-phosphate, CO₂ | G6PD is the committed step; inhibited by NADPH and by acetyl-CoA competition |
| Non-oxidative | Transketolase, transaldolase, ribose-5-phosphate isomerase/epimerase | Ribose-5-phosphate, glycolytic intermediates | Reversible; direction depends on substrate and demand |
Important distinction. The oxidative branch is irreversible and produces NADPH; the non-oxidative branch is reversible, produces no NADPH, and can either supply ribose or return carbon to glycolysis. A claim that "PPP flux increased" must specify which branch, because the two move independently and are measured by different methods.
The non-oxidative branch is also the reason PPP flux can be high when G6PD activity is low: ribose can be produced from glycolytic intermediates in reverse, and G6PD-deficient cells can still support nucleotide synthesis if the non-oxidative route is available.
Part 1 — NADPH: Four Sources, Five Consumers
| Role | Route | Note |
|---|---|---|
| Source | PPP oxidative branch | Cytosolic; the canonical source |
| Source | Malic enzyme (ME1 cytosolic, ME3 mitochondrial) | Couples to pyruvate cycling |
| Source | Isocitrate dehydrogenase (IDH1 cytosolic, IDH2 mitochondrial) | Mitochondrial IDH2 is a major source in some tissues |
| Source | One-carbon/folate metabolism | MTHFD1/2 contribute in proliferating cells |
| Consumer | Fatty acid and sterol synthesis | ACC, FASN, HMGCR |
| Consumer | Glutathione reductase and thioredoxin reductase | Determines redox buffering |
| Consumer | NADPH oxidases (NOX family) | Deliberate production of superoxide |
| Consumer | Cytochrome P450 and other monooxygenases | Hepatic and steroidogenic |
| Consumer | Nitric oxide synthase | Context-dependent |
Caveat on redundancy. Because four routes supply NADPH, a G6PD knockout or knockdown may leave the NADPH/NADP⁺ ratio unchanged while reducing flux through the oxidative branch. The correct readout for a pathway claim is a PPP-specific measurement; the ratio is a readout of net balance, and it can be defended by a different route.
The same redundancy applies in reverse: a rise in NADPH does not identify its source. Attributing it to the PPP requires showing that PPP flux rose, or that removing the PPP prevents the rise.
Part 2 — Measuring the Oxidative Branch
| Method | What it measures | Assumptions |
|---|---|---|
| ¹⁴CO₂ or ¹³CO₂ release from [1-¹⁴C] or [1-¹³C]glucose | Decarboxylation at 6PGD | The released CO₂ comes from the oxidative branch; no recycling |
| Ratio of C1 to C6 oxidation | Relative oxidative PPP versus glycolysis plus TCA | C6 oxidation requires mitochondrial activity; cells with low respiration distort the ratio |
| Ribose labelling from ¹³C-glucose | Ribose synthesis | Does not distinguish oxidative from non-oxidative contribution without positional analysis |
| G6PD activity assay on lysate | Enzyme capacity | Capacity, not flux |
| NADPH/NADP⁺ ratio | Net redox balance | Extraction artefacts; see below |
Readout note. The C1/C6 ratio is the most widely used PPP index and the least robust in isolation. It assumes that C1 decarboxylation reports the oxidative PPP and that C6 decarboxylation reports the TCA cycle, and both assumptions break when the cycle is rewired — for example, under glutamine-dependent anaplerosis or when the non-oxidative branch is running in reverse. Use it as one of at least two measurements.
Part 3 — Measuring the Non-Oxidative Branch
The non-oxidative branch is harder, because it is reversible and produces no unique product.
| Approach | What it can show | Limitation |
|---|---|---|
| Ribose labelling from [1,2-¹³C]glucose with positional analysis | Whether ribose carbon came through the oxidative or non-oxidative route | Requires mass isotopomer and positional analysis; interpretation depends on the model |
| Sedoheptulose-7-phosphate or erythrose-4-phosphate pools | Intermediate accumulation or depletion | Pools are small and turnover is fast |
| Transketolase/transaldolase knockdown or knockout | Requirement for the branch | Compensation and growth effects |
| Nucleotide synthesis rate | Downstream demand | Not specific to the branch |
A practical compromise for most studies is to measure the oxidative branch directly, measure ribose labelling for total ribose production, and perturb the non-oxidative enzymes only when the claim requires it. Claiming non-oxidative flux from a C1/C6 ratio alone is not supportable.
Part 4 — The NADPH/NADP⁺ Ratio: A Measurement That Fails Quietly
The ratio is biologically important and analytically treacherous.
| Problem | Mechanism | Mitigation |
|---|---|---|
| Rapid interconversion during extraction | NADPH oxidises, NADP⁺ is reduced by dehydrogenases | Immediate quench in cold acid or base per the assay's requirement; work fast and cold |
| Differential stability | NADPH and NADP⁺ degrade at different rates | Validate recovery with spiked standards |
| Compartment mixing | Cytosolic and mitochondrial pools differ | Accept that bulk ratios are averages; use genetically encoded sensors if compartment matters |
| Alkaline versus acid extraction | Different assays require different conditions; the two are incompatible in one aliquot | Split the sample; follow the kit's chemistry |
| Coupling artefacts in cycling assays | Enzymatic recycling amplifies both signal and interference | Include a spike-recovery control and a no-enzyme blank |
Important distinction. A ratio change can arise from a change in production, in consumption, or in total pool size. Reporting the ratio without the total nicotinamide pool leaves the direction of the change ambiguous: a fall in the ratio can reflect more NADP⁺ production without any change in NADPH.
Part 5 — What a PPP Claim Requires
| Claim | Minimum evidence | What does not count |
|---|---|---|
| "Oxidative PPP flux increased" | CO₂ release from C1 glucose plus an independent measurement (ribose labelling or NADPH production with source attribution) | G6PD mRNA; G6PD lysate activity |
| "NADPH supply is limiting" | A perturbation that reduces NADPH, a phenotype, and rescue with an NADPH-generating enzyme or a downstream antioxidant | A correlation between the ratio and growth |
| "The non-oxidative branch supplies ribose" | Positional labelling, or a transketolase perturbation with a nucleotide-synthesis readout | Total ribose labelling alone |
| "G6PD is required for survival under oxidative stress" | G6PD loss plus an oxidant challenge, with rescue by NADPH or by glutathione | Baseline growth difference |
Part 6 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Defined glucose concentration | PPP flux scales with glucose supply |
| Documented oxygen tension | C1/C6 interpretation assumes mitochondrial activity |
| Proliferation measured | Ribose demand follows nucleotide synthesis |
| Redox challenge specified, if used | The PPP response depends on the oxidant and its dose |
| Extraction validated for NADPH | The ratio is fragile |
| At least two PPP measurements | No single method is decisive |
Recurring failures:
- • G6PD expression or lysate activity reported as PPP flux.
- • C1/C6 ratio reported as branch-specific flux in a cell with rewired mitochondrial metabolism.
- • NADPH/NADP⁺ ratio reported without the total pool.
- • NADPH source attributed to the PPP because the PPP is the best-known source.
- • Non-oxidative flux claimed from a method that cannot resolve direction.
- • Oxidant dose not titrated, so the "PPP activation" is a cytotoxicity response.
- • Proliferation unmeasured, although ribose demand is the main driver in dividing cells.
Part 7 — Where This Article Connects
The PPP sits at the branch point between the pillar's glycolytic module and its biosynthetic outputs: glucose-6-phosphate can go to glycolysis, to the PPP, or to glycogen, and the partition changes with demand. The glycogen article in this cluster covers the third branch; the glucose-tracing articles cover the methods for distinguishing them; and the redox domain of this site owns the glutathione and thioredoxin consumers.
If you need PPP flux resolved by branch with validated NADPH measurement, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
PPP flux, G6PD regulation and NADPH source attribution vary by cell type, proliferation rate and oxidative challenge; the directions described here are common patterns, not fixed relationships.
A change in the NADPH/NADP⁺ ratio does not establish a change in PPP flux, and a change in G6PD activity does not establish a change in pathway flux in the cell.
Scientific interpretation and experimental design
- • Two branches, two methods. Oxidative is irreversible and measurable; non-oxidative is reversible and needs positional analysis.
- • Four sources of NADPH. Ratio changes do not identify the source.
- • C1/C6 is one measurement. Use it with a second.
- • The ratio needs the total pool. Otherwise the direction is ambiguous.
- • Extraction kills this assay. Quench fast, split aliquots, spike for recovery.
- • Proliferation drives ribose demand. Measure it.
Selected references for further reading
- • Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 2012;64:362–369.
- • Fan J, et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014;510:298–302.
- • Lewis CA, et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Molecular Cell. 2014;55:253–263.
- • Chen L, et al. NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. Nature Metabolism. 2019;1:404–415.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »